Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)

Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)

<b>Objective:</b> This study aimed to assess the role of Tocilizumab therapy (TCZ) in terms of ICU admission and mortality rate of critically ill patients with severe COVID-19 pneumonia. <b>Design:</b> Patients with COVID-19 pneumonia were prospectively enrolled in SMAtteo CO...

Full description

Bibliographic Details
Main Authors: Marta Colaneri, Laura Bogliolo, Pietro Valsecchi, Paolo Sacchi, Valentina Zuccaro, Fabio Brandolino, Carlomaurizio Montecucco, Francesco Mojoli, Emanuele Maria Giusti, Raffaele Bruno, the COVID IRCCS San Matteo Pavia Task Force
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Microorganisms
Subjects:
tocilizumab
off label therapy
propensity score matching
COVID-19 pneumonia
ICU
mortality rate
Online Access:https://www.mdpi.com/2076-2607/8/5/695

Internet

https://www.mdpi.com/2076-2607/8/5/695

Similar Items